Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)
Saint Louis University · Harvard University · +4 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,863
total citations
- FWCI
- 42.74
- Percentile
- 100%
- References
- 45
Citations per year
Authors
9Topics & keywords
Topics
Keywords
- Ustekinumab
- Medicine
- Psoriasis
- Psoriasis Area and Severity Index
- Placebo
- Clinical endpoint
- Internal medicine
- Randomization
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.